行情

BPMC

BPMC

蓝图医药
NASDAQ

实时行情|Nasdaq Last Sale

75.03
+0.40
+0.53%
交易中 13:52 08/07 EDT
开盘
74.28
昨收
74.63
最高
76.14
最低
74.10
成交量
10.60万
成交额
--
52周最高
93.90
52周最低
43.29
市值
41.47亿
市盈率(TTM)
-9.7957
分时
5日
1月
3月
1年
5年

分析师评级

15位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测BPMC价格均价为97.36,最高价位110.00,最低价为76.00。

EPS

BPMC 新闻

更多
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on August 1, 2020, the Compensation Committee of Blueprint Medicines' Bo
PR Newswire · 3天前
Blueprint Medicines' (BPMC) Q2 Earnings Miss, Revenues Beat
Blueprint Medicines (BPMC) posts a wider-than-expected loss but revenues beat estimates in the second quarter of 2020.
Zacks · 07/31 15:18
Blueprint Medicines EPS misses by $0.15, beats on revenue
Blueprint Medicines (NASDAQ:BPMC): Q2 GAAP EPS of -$2.28 misses by $0.15. Revenue of $8.34M (+63.2% Y/Y) beats by $1.41M. Press Release
seekingalpha · 07/30 16:05
Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -9.62% and 10.36%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 07/30 12:35
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)
Benzinga · 07/30 12:09
Blueprint Medicines Q2 EPS $(2.28) Misses $(2.14) Estimate, Sales $8.34M Beat $6.60M Estimate
Blueprint Medicines (NASDAQ:BPMC) reported quarterly losses of $(2.28) per share which missed the analyst consensus estimate of $(2.14) by 6.54 percent. This is a 11.76 percent decrease over losses of $(2.04) per share
Benzinga · 07/30 11:45
Blueprint Medicines Reports Second Quarter 2020 Financial Results
Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported financial results and provided a business update for the second quarter ended June 30, 202
PR Newswire · 07/30 11:00
Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha · 07/30 04:00

所属板块

生物技术和医学研究
-0.07%
制药与医学研究
-0.27%

热门股票

代码
价格
涨跌幅

BPMC 简况

Blueprint Medicines Corporation是一家生物制药公司。该公司专注于由异常激酶激活引起的遗传病患者。该公司专注于生产具有治疗窗口的候选药品,为没有足够治疗选择的患者提供临床药物。该公司在癌症和遗传性疾病方面开发了小分子药物。该公司的候选药物,BLU-285靶向KIT外显子17突变体和PDGFRa D842V,它们是异常活性的受体酪氨酸激酶突变体,是癌症和增殖性疾病的驱动因子。该公司为患有系统性肥大细胞增多症(SM)、肥大细胞骨髓增值性疾病和患有胃肠道间质瘤(GIST)患者亚组的患者开发BLU-285。其候选药物,BLU-554靶向FGFR4。FGFR4为一种激酶,被异常激活并且是肝细胞癌(HCC)患者亚群疾病的激活者。
展开

微牛提供Blueprint Medicines Corp(NASDAQ-BPMC)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的BPMC股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易BPMC股票基本功能。